A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Inclusion Criteria:

- Chronic HCV infection prior to study enrollment.

- Screening laboratory result indicating HCV genotype 1-infection.

- Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening.

- Per local standard, subject is considered to be non-cirrhotic or to have compensated
cirrhosis.

Exclusion Criteria:

- History of severe, life-threatening or other significant sensitivity to any drug.

- Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human
Immunodeficiency Virus antibody (HIV Ab).

- Prior therapy for the treatment of HCV.

- Any current or past clinical evidence of Child Pugh B or C classification of clinical
history of liver decompensation including ascites (noted on physical exam), variceal
bleeding or hepatic encephalopathy.

- Any cause of liver disease other than chronic HCV infection.